Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia
- 1 July 2004
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 94 (2), 157-161
- https://doi.org/10.1016/j.amjcard.2004.03.052
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary interventionEuropean Heart Journal, 2003
- Asymmetrical dimethylarginine: A novel risk factor for coronary artery diseaseClinical Cardiology, 2003
- Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthase InhibitorJAMA, 2002
- Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective studyThe Lancet, 2001
- Risk of acute coronary events and serum concentration of asymmetrical dimethylarginineThe Lancet, 2001
- Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitusThe American Journal of Cardiology, 2001
- Biological significance of endogenous methylarginines that inhibit nitric oxide synthasesCardiovascular Research, 1999
- Reduced Urinary Excretion of Nitric Oxide Metabolites and Increased Plasma Levels of Asymmetric Dimethylarginine in Men with Essential HypertensionJournal of Cardiovascular Pharmacology, 1999
- Endogenous Nitric Oxide Synthase InhibitorCirculation, 1999
- Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial DysfunctionCirculation, 1998